Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended September 30, 2023 and 2022 is as follows:

	Three Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	1,427	$	2,359		$	-			$	3,786
Gross profit		-			1,029		(845	)		-				184
Direct expenses		4,887			350		1,901			9,074				16,212
Segment contribution	$	(4,887	)	$	679	$	(2,746	)		(9,074	)			(16,028	)
Indirect expenses										83,228		(a)		83,228
Loss from operations													$	(99,256	)
(a) Components of other
Change in fair value of contingent consideration liability										-
Change in fair value of contingent stock consideration										(39	)
Goodwill impairment										82,714
IPR&D impairment										-
Amortization										553
Total other									$	83,228

	Three Months Ended September 30, 2022
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	1,405	$	2,730		$	-			$	4,135
Gross profit		-			506		(3,584	)		-				(3,078	)
Direct expenses		19,863			432		3,194			11,965				35,454
Segment contribution	$	(19,863	)	$	74	$	(6,778	)		(11,965	)			(38,532	)
Indirect expenses										(32,886	)	(b)		(32,886	)
Income from operations													$	(5,646	)
(b) Components of other
Change in fair value of contingent consideration liability										(33,243	)
Change in fair value of contingent stock consideration										(196	)
Amortization										553
Total other									$	(32,886	)

Financial information by segment for the nine months ended September 30, 2023 and 2022 is as follows:

	Nine Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	4,062	$	6,597		$	-			$	10,659
Gross profit		-			2,707		1,545			-				4,252
Direct expenses		53,505			780		6,799			31,481				92,565
Segment contribution	$	(53,505	)	$	1,927	$	(5,254	)		(31,481	)			(88,313	)
Indirect expenses										117,289		(c)		117,289
Loss from operations													$	(205,602	)
(c) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Change in fair value of contingent stock consideration										(159	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										1,640
Total other									$	117,289

	Nine Months Ended September 30, 2022
	Cell Therapy			BioBanking			Degenerative Disease			Other				Total
Net sales	$	-		$	4,061		$	9,785		$	-			$	13,846
Gross profit		-			949			(1,521	)		-				(572	)
Direct expenses		65,896			1,314			7,832			38,857				113,899
Segment contribution	$	(65,896	)	$	(365	)	$	(9,353	)		(38,857	)			(114,471	)
Indirect expenses											(71,386	)	(d)		(71,386	)
Loss from operations														$	(43,085	)
(d) Components of other
Change in fair value of contingent consideration liability											(73,441	)
Change in fair value of contingent stock consideration											415
Amortization											1,640
Total other										$	(71,386	)